IQV

IQVIAC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The constructive case is that Q1 showed broad execution rather than a one-off beat: Commercial Solutions grew 11.6%, R&D Solutions grew 6.2%, free cash flow reached $491M, and management raised FY2026 adjusted EPS guidance while reaffirming revenue and EBITDA guidance [#IR-2026-05-05]. With the stock at $170.68 versus a packet median target of $234.19, there is room for recovery if backlog conversion and commercial growth hold.

Posture

Mixed

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.1.

What can break

Backlog conversion risk remains central; management highlighted expected 12-month conversion, but the pace at which backlog converts into revenue remains a key operating risk [#10-Q-2026-05-05].

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $188.00 · Bull $215.00 · Bear $150.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $230.00

Why

Momentum51 · Δ7d -2.1

Value66 · Δ7d -0.1

Sentiment36 · Δ7d -2.1

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

-2.1

Δ21d

-1.4

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

-0.3

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-2.1

Δ21d

-8.6

Why this grade

Composite grade C. Momentum 51.4 / Value 65.6 / Sentiment 35.6

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$34.42B

Beta

1.37

Shares Out

166.9M

P/E (TTM)

32.2

P/S (TTM)

2.51

P/FCF (TTM)

18.07

Rev YoY

+8.6%

EPS YoY

+15.0%

Gross Margin

+26.0%

Op Margin

+13.7%

Net Debt

$14.12B

Current Ratio

0.75

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology